Added to YB: 2025-06-06
Pitch date: 2025-06-05
HRMY [bullish]
Harmony Biosciences Holdings, Inc.
+4.55%
current return
Author Info
No bio for this author
Company Info
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.
Market Cap
$2.1B
Pitch Price
$35.40
Price Target
52.00 (+41%)
Dividend
N/A
EV/EBITDA
7.28
P/E
14.31
EV/Sales
1.75
Sector
Pharmaceuticals
Category
growth
Harmony Biosciences, the best play in Biotech sector?
HRMY: Commercial-stage pharma w/ WAKIX ($715M 2024 rev, 30% EBITDA margin) targeting $1B+ narcolepsy market by 2030. Pipeline includes ZYN002 (Phase 3 for FXS, data Q3'25). Undervalued at 2.7x P/S, 13.5x P/E vs biotech peers. $507M cash, $158M debt. PT $70 (100% upside).
Read full article (5 min)